Author Archives: David Melamed, PhD

Catalyst Given US Patent Covering Firdapse in Treating LEMS

The U.S. Patent and Trademark Office has issued a new patent to Catalyst Pharmaceuticals covering the company’s rights to Firdapse (amifampridine), a treatment for Lambert-Eaton myasthenic syndrome (LEMS). The patent (No. 10,793,893), “Methods of administering 3,4-diaminopyridine,” expires on April 7, 2034. Catalyst’s rights over Firdapse…